Literature DB >> 1587622

Early complement components enhance neutralization of Chlamydia trachomatis infectivity by human sera.

J S Lin1, L L Yan, Y Ho, P A Rice.   

Abstract

Immunoglobulin G in human serum neutralizes chlamydial infectivity in vitro. Complement-intact, C5-depleted, and C8-depleted human serum all have significantly more neutralizing activity than serum heated to inactivate early components of complement. Cobra venom factor, an analog of human C3b, enhances neutralization of antichlamydial immunoglobulin G in the absence of early complement components.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1587622      PMCID： PMC257196          DOI： 10.1128/iai.60.6.2547-2550.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  18 in total

Review 1.  Molecular aspects of C3 interactions and structural/functional analysis of C3 from different species.

Authors:  J D Becherer; J Alsenz; J D Lambris
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

Review 2.  Complement evasion by bacteria and parasites.

Authors:  K A Joiner
Journal:  Annu Rev Microbiol       Date:  1988       Impact factor: 15.500

3.  Differences in susceptibilities of the lymphogranuloma venereum and trachoma biovars of Chlamydia trachomatis to neutralization by immune sera.

Authors:  E M Peterson; M Hoshiko; B A Markoff; M W Lauermann; L M de la Maza
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

4.  Complement enhancement of neutralizing antibody to the structural proteins of Chlamydia trachomatis.

Authors:  D W Megran; H G Stiver; R Peeling; I W Maclean; R C Brunham
Journal:  J Infect Dis       Date:  1988-09       Impact factor: 5.226

Review 5.  Participation of C3 and its ligands in complement activation.

Authors:  J E Volanakis
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

6.  Susceptibility of different serovars of Chlamydia trachomatis to inactivation by normal human serum.

Authors:  M F Osborn; A P Johnson; D Taylor-Robinson
Journal:  Genitourin Med       Date:  1985-08

7.  Inhibition of human neutrophil NADPH oxidase by Chlamydia serovars E, K, and L2.

Authors:  A I Tauber; N Pavlotsky; J S Lin; P A Rice
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

8.  Rapid immunotyping of Chlamydia trachomatis with monoclonal antibodies in a solid-phase enzyme immunoassay.

Authors:  R C Barnes; S P Wang; C C Kuo; W E Stamm
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

9.  Neutralization of Chlamydia trachomatis infectivity with antibodies to the major outer membrane protein.

Authors:  H D Caldwell; L J Perry
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

10.  In vitro neutralization of Chlamydia trachomatis with monoclonal antibody to an epitope on the major outer membrane protein.

Authors:  R Peeling; I W Maclean; R C Brunham
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441
View more
  12 in total

1.  Native properdin binds to Chlamydia pneumoniae and promotes complement activation.

Authors:  Claudio Cortes; V P Ferreira; Michael K Pangburn
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

2.  Complement factor C5 but not C3 contributes significantly to hydrosalpinx development in mice infected with Chlamydia muridarum.

Authors:  Zhangsheng Yang; Turner Conrad; Zhou Zhou; Jianlin Chen; Pavel Dutow; Andreas Klos; Guangming Zhong
Journal:  Infect Immun       Date:  2014-05-19       Impact factor: 3.441

Review 3.  Killing me softly: chlamydial use of proteolysis for evading host defenses.

Authors:  Guangming Zhong
Journal:  Trends Microbiol       Date:  2009-09-16       Impact factor: 17.079

4.  Characterization of kinetics and target proteins for binding of human complement component C3 to the surface-exposed outer membrane of Chlamydia trachomatis serovar L2.

Authors:  R T Hall; T Strugnell; X Wu; D V Devine; H G Stiver
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

5.  The complement C3a receptor is critical in defense against Chlamydia psittaci in mouse lung infection and required for antibody and optimal T cell response.

Authors:  Pavel Dutow; Beate Fehlhaber; Jenny Bode; Robert Laudeley; Claudia Rheinheimer; Silke Glage; Rick A Wetsel; Oliver Pabst; Andreas Klos
Journal:  J Infect Dis       Date:  2013-11-23       Impact factor: 5.226

6.  Chlamydia infection status, genotype, and age-related macular degeneration.

Authors:  Sam Khandhadia; Sebastian Foster; Angela Cree; Helen Griffiths; Clive Osmond; Srinivas Goverdhan; Andrew Lotery
Journal:  Mol Vis       Date:  2012-01-10       Impact factor: 2.367

7.  Complement and Chlamydia psittaci: Early Complement-Dependent Events Are Important for DC Migration and Protection During Mouse Lung Infection.

Authors:  Martin Kohn; Christian Lanfermann; Robert Laudeley; Silke Glage; Claudia Rheinheimer; Andreas Klos
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

8.  A new role of the complement system: C3 provides protection in a mouse model of lung infection with intracellular Chlamydia psittaci.

Authors:  Jenny Bode; Pavel Dutow; Kirsten Sommer; Katrin Janik; Silke Glage; Burkhard Tümmler; Antje Munder; Robert Laudeley; Konrad W Sachse; Andreas Klos
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

9.  Perforin is detrimental to controlling [corrected] C. muridarum replication in vitro, but not in vivo.

Authors:  Raymond M Johnson; Micah S Kerr; James E Slaven
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

Review 10.  An Ancient Molecular Arms Race: Chlamydia vs. Membrane Attack Complex/Perforin (MACPF) Domain Proteins.

Authors:  Gabrielle Keb; Kenneth A Fields
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.